冠心合剂主要活性成分对TNF-α损伤人脐静脉内皮细胞ICAM-1和VCAM-1mRNA的表达的影响研究  

Effect of Main Active Ingredient of Guanxin Decoction on ICAM-1 and VCAM-1 Expressions of HUVECs Exposed to TNF-α

作　　者：祝光礼[1] 陈铁龙[1] 方伟[1] 毛立华[1] 刘宏飞[1] 

机构地区：[1]浙江中医药大学附属广兴中医院心内科,浙江杭州310007

出　　处：《中华中医药学刊》2013年第12期2692-2694,共3页Chinese Archives of Traditional Chinese Medicine

基　　金：浙江省自然科学基金资助项目(Y2080946)

摘　　要：目的:探讨冠心合剂主要活性成分对TNF-α刺激下人脐静脉内皮细胞(HUVECs)细胞间黏附分子-1(ICAM-1)、血管黏附分子-1(VCAM-1)mRNA基因表达影响。方法:采用人脐静脉内皮细胞培养传代后作为实验对象,随机分为正常对照组、模型组、黄芪甲苷组、槲皮素组、异鼠李素组、β谷甾醇组。以浓度为2 ng/mL的TNF-α刺激HUVECs 6 h后,分别再加入各药物成分(黄芪甲苷80μg/mL、槲皮素30μg/mL、异鼠李素20μg/mL、β谷甾醇20μg/mL),与HUVECs共培养18 h后,用RT-PCR法检测ICAM-l、VCAM-l mRNA的表达水平。结果:黄芪甲苷、槲皮素、异鼠李素组均可降低TNF-α诱导的HUVECs的ICAM-l、VCAM-l mRNA表达(P<0.01、P<0.01、P<0.01),其中黄芪甲苷组较其他三组有显著统计学意义(P<0.05);但β谷甾醇组与各组相比较,差异无统计学意义(P>0.05)。结论:冠心合剂主要活性成分黄芪甲苷等对TNF-α损伤人血管内皮细胞的保护作用可能源于对ICAM-l、VCAM-1 mRNA表达的抑制。Objective： To explore the effects of Guanxin Decoction on ICAM - 1 and VCAM - 1 expressions of HU- VECs exposed to TNF-α . Methods ： The cultured HUVECs from third to sixth generations were randomly divided into the trial group and the control group （ model group, control group, Astragaloside group, Quercetin group, Isorhamnetin group, β -Sitosterol group）. And then HUVECs were cultured with TNF-α secondly,＇after 6 hours, stimulated with the main ac- tive ingredient of Guanxin Decoction for 18 hours. ICAM - 1 and VCAM - 1 were detected by reverse transcriptase poly- merase chain reaction （RT- PCR） in HUVECs. Results： The group of Astragaloside, Quercetin and Isorhamnetin can significantly inhibit ICAM - 1 and VCAM - 1 expressions in HUVECs exposed to TNF - ct and Astragaloside group was better than Quercetin and Isorhamnetin group. But ~ - Sitosterol group had no significant difference compared with other groups. Conclusion： Guanxin Decoction has anti - athemgenic effect due to inhibit the expressions of ICAM - 1 and VCAM - 1.

关 键 词：动脉粥样硬化 细胞黏附分子-l 血管细胞黏附分子-1 人脐静脉内皮细胞 冠心合剂 

分 类 号：R285.5[医药卫生—中药学]